may be enhanced via multiple cellular mechanisms resulting in varied effects on cardiac energetics. The mechanisms that account for the varied energetic responses are not well understood. The purpose of this investigation was to compare the effects of the calcium sensitizing agent ORG 30029 (N-hydroxy-5,6-dimethoxy-benzo[b]thiophene-2-carboximidamide hydrochloride, a calcium sensitizing agent which increases contractility without increasing calcium transients significantly), dobutamine and high perfusate calcium on contractility and energetics. Langendorff-perfused rat hearts were stimulated with ORG 30029, dobutamine and high perfusate calcium in graduated concentrations while myocardial oxygen consumption (MVO 2 ) and force-time integral were measured. ORG 30029, dobutamine and high perfusate calcium increased contractility in a dose-dependent manner. Despite an increase of 50% in systolic pressure and a 17% increase in force-time integral from control, ORG 30029 had no significant effect on MVO 2 at the lower concentrations (n=6). However, dobutamine (n=4) and high perfusate calcium (n=4) caused a 65% increase in systolic pressure and a 17% increase in force-time integral and a 50% and 41% increase in MVO 2 respectively (P<0.05). High energy phosphates (by 31 P NMR), and lactate production were unaltered by these agents, suggesting that metabolism was steady state. Basal metabolism tended to increase slightly with dobutamine but not with ORG 30029 or high perfusate calcium. ORG 30029, dobutamine, and high perfusate calcium increase contractility in perfused rat hearts with disparate effects on energetics. These differences may be accounted for, in part, by differences in energy expenditure for calcium handling.
Introduction
agents on cardiac energetics have yielded various results. Some studies have shown that increasing Cardiac contractility may be enhanced via multiple cellular mechanisms with varied effects on cardiac calcium sensitivity increases contractility in a more energetically efficient manner than inotropic agents energetics (Alpert et al., 1992) . When contractile force is increased by an elevation in the calcium which increase the calcium transient amplitude (Aoyagi et al., 1991 , Groß et al., 1993 . However, transient (the rise in intracellular calcium concentration during depolarization) there is a proother studies have not found any difference in efficiency (deTombe et al., 1992 , Hata et al., 1992 . portionate rise in myocardial oxygen consumption (MVO 2 ) (Wu et al., 1992) . Contractility may also
We previously compared the effects of the unique calcium sensitizing agent EMD 57033, which does be increased by enhancing the "sensitivity" of the contractile proteins to calcium (Lee and Allen, not affect calcium transients (Gambassi et al., 1993 , Solaro et al., 1993 , to dobutamine in isolated rat perfusion pressure of 80 mmHg. Coronary perfusion pressure was measured via an in-line pressure hearts. In that study, despite a 40% increase in cardiac work, dobutamine increased MVO 2 47%
transducer. Perfusate was not recirculated. To measure left ventricular pressure, a water-filled latex while EMD 57033 did not cause any significant increase in MVO 2 (Grandis et al., 1995) . Doballoon attached to 3 cm non-compliant tubing was placed through the mitral valve into the left butamine has 1 agonist properties and may decrease calcium sensitivity (Ruffulo, 1987, Endoh ventricle. Left ventricular pressure was determined using a pressure transucer (Gould, Cleveland, OH). and Blinks, 1989) . Thus, the different effects of the two agents on calcium sensitivity could have caused
To assure a uniform heart rate in all studies, hearts were placed at 5 Hz using a stimulator and the different energetic responses. Conversely, the energetic differences may be accounted for by difnon-metallic pacing leads (KCl-agar) attached to the right ventricular apex. To eliminate autonomous ferences in the energetic costs of calcium handling. Finally, because dobutamine shortened duration of beating, the atria was removed and the AV node was crushed. Left ventricular diastolic pressure was contraction significantly and EMD 57033 did not, it was impossible to compare the effects on enset at 8 mmHg pressure during the initial equilibration period by adjusting the intraventricular ergetics of dobutamine and EMD 57033 at similar increases in force-time integral.
balloon volume. The mean volume of the balloon was 0.1±0.04 ml. If the left ventricular systolic ORG 30029 (N-hydroxy-5,6-dimethoxy-benzo[b]-thiophene-2-carboximidamide hydrochloride) is a pressure did not reach 80 mmHg the heart was not used. cardiotonic agent which increases contractility both by inhibition of phosphodiesterase activity as well
The perfusate was a modified Krebs-Henseleit buffer containing the following constitutents: as via calcium sensitizing (Cottney et al., 1990) . ORG 30029 has been demonstrated to increase 115 m NaCl, 4.5 m KCl, 26 m NaHCO 3 , 1.8 m MgSO 4 , 2.0 m CaCl 2 , 0.1 m NaEDTA, 10 m contractility several-fold with minimal effects on calcium transients (Kawabata and Endoh, 1993) .
pyruvate and 11 m glucose (Neely et al., 1967) . KH 2 PO 4 was excluded from the buffer to enable The purpose of this investigation was to compare the energetic effects of increasing contractility via accurate measurements of intracellular inorganic phosphate (P i ) from 31 P NMR. Pyruvate was added graded concentrations of ORG 30029 to that of dobutamine and high perfusate calcium, both of to the buffer to maximize the redox state of the heart mitochondria and minimize the production of which increase calcium transients significantly. High perfusate calcium concentration was em-ATP by glycolysis (Kingsley-Hickman et al., 1986) . Perfusate osmolarity was determined (Wescor vapor ployed because it is able to increase contractility without 1 agonism or shortened duration of conpressure osmometer) to be between 285 and 295 mOsm. To eliminate the effects of catecholamine traction, like dobutamine (deTombe et al., 1992) . At lower concentrations, ORG 30029 caused sigrelease by pacing, 0.1  esmolol (Dupont, Wilmington, DE) was added to the buffer. Perfusate nificantly less of an increase in MVO 2 than did dobutamine and high perfusate calcium. To probe temperature was maintained at 37°C via an in-line thermistor and heat exchanger. The perfusate was possible mechanisms for this difference in MVO 2 at these concentrations, lactate production, phosphate oxygenated by vigorous bubbling of the solution with a mixture of 95% O 2 and 5% CO 2 . The pH of metabolite concentrations (by 31 P NMR), and basal metabolism were determined with each agent.
the perfusate was 7.40. At the end of each experiment, the hearts were removed from the cannula and weighed. Hearts were air dried for 2 days and weighed again for the dry weight.
Materials and Methods

Heart perfusion Oxygen consumption
Male Sprague-Dawley rats (Taconic Farms, GerMyocardial oxygen consumption (MVO 2 ) was determined by the product of perfusate flow rate mantown, N.Y.) weighing 325-350 g were fasted overnight. Animals were anesthetized with 50 mg and the difference between afferent and efferent perfusate oxygen content. To avoid exchange bepentobarbital and anticoagulated with 1000 U heparin intraperitoneally. Hearts were excised and pertween the effluent perfusate and ambient air, the heart was suspended in a small, closed glass chamfused within 15 s in the Langendorff manner (Neely et al., 1967) . Hearts were perfused at a constant ber. Effluent dripped off the heart but hearts were suspended in effluent. Samples were obtained at the and Veech, 1979 ] from spectra during each period were averaged for the control period and each 31 P NMR spectroscopy inotropic agent.
[ATP] and [TOTAL CREATINE] were determined by HPLC as previously described.
31
P NMR measurements were made using a 4.7 Tesla, 40 cm horizontal bore Bruker Biospec NMR spectrometer (Bruker Inst., Billerica, MA) which operates at a phosphorus frequency of 81 MHz. 31 
P
Lactate production NMR spectra were obtained from the isolated heart in a closed chamber which was suspended and Lactate production was determined by measuring the difference in lactate concentrations between the centered in a 2 cm diameter solenoid radio frequency coil tuned to the 31 P frequency. Spectra perfusate entering and exiting the heart. Lactate concentration was determined using a standard were acquired using a 90°pulse and an 8 s repetition time. Eighty acquisitions were averaged; commercial assay (Sigma Chemical Co., Kit #735, St Louis, MO). Three measurements were made requiring 10.7 min of acquisition time. The areas of the peaks were determined using the Bruker during control period and during the infusion of the agents. integration method.
The following procedure was used to determine the relation between peak areas and the concentration of metabolites. In a separate set of exExperimental protocol periments, the degree of saturation with the protocol above was determined by obtaining spectra Throughout the entire experiment, left ventricular pressure was continuously measured while MVO 2 both in the fully relaxed state (15 s) and with an 8 s repetition time. Based on HPLC analysis, the lactate production, and 31 P NMR spectra were obtained every 8-10 min. A control steady-state was concentration of ATP in hearts was determined to be 24.7 mol/g dry weight (Grandis et al., 1995) .
established when three consecutive measurements of the 31 P NMR spectra, MVO 2 , and pressure did The peak areas of phosphocreatine (PCr) and P i were compared to the peak area of the ATP peak.
not vary by more than 10%. This period was approximately 35 min in duration. In three separate Using the known [ATP] from high performance liquid chromatography (HPLC) as the value of the experiments, no inotropic agents were infused and demonstrated that cardiac function, MVO 2 and 31 P ATP peak and the respective saturation factors for ATP, PCr and P i , the concentrations of [PCr] NMR spectra were stable in this model for over 120 min (data not shown). and [P i ] were determined.
All chemical shifts were determined relative to After a control steady-state was established, the perfusate was changed to the same perfusate with PCr which was assigned a shift of 0 ppm. Intracellular pH was determined as previously described an inotropic agent added at a particular concentration. Each experiment used only one agent from the chemical shift of the P i peak and [Mg 2+ ] was determined from the chemical shift difference at one concentration per study. ORG 30029 was kindly donated by Organon Pharmaceuticals. It is between the and ATP peaks (Koretsky et al., 1989) . Free [ADP] was determined assuming the relatively insoluble in water and thus was disolved in DMSO (Fisher, Pittsburgh, PA). The DMSO socreatine kinase catalyzed reaction was in equilibrium (Veech et al., 1979) 
lution was added to the perfusion buffer to yield a final DMSO to water concentration of 1:1800. In and pH were determined by 31 P NMR and HPLC (From et al., 1986 ). An average total creatine ([PCr] a separate set of experiments, DMSO alone was added to buffer at a concentration of up to 1:1000 and [Cr]) was determined to be 62.1 mol/g dry weight by HPLC. The equilibrium constant for the and had no effect on cardiac metabolism or function (data not shown). Dobutamine (Eli Lilly, Increatine kinase reaction, K app , was calculated for each heart, accounting for pH and [Mg 2+ ] (Lawson dianapolis, IN) and calcium were added directly to . To calculate balloon surface area, it was assumed that the balloon was spherical. The force-time integral was expressed in kilodynes·seconds (kdyne·secs).
Basal metabolism
The functional, metabolic, and 31 P NMR data obtained in the control steady-state period from all To determine the effects of these inotropic agents experiments were pooled. Analysis of variance for on basal metabolism, rat hearts were perfused at repeated measures were used to determine difconstant pressure with the perfusate and conditions ferences within study populations and a post hoc above while left ventricular pressure and MVO 2 Bonferroni/Dunn "t" test was used to test for sigwere monitored. After a steady-state was achieved, nificant differences between groups. Data are exhearts were arrested by changing the perfusate to pressed as means±standard deviation. The number one that was the same as control perfusate but of experiments are shown in the Tables. contained 20 mM KCl. This concentration was chosen because it is the concentration which was found to suppress all autonomous beating of the heart in the presence of dobutamine. After an Results arrested steady-state was achieved, the inotropic agents were added to the perfusate as described ORG 30029, dobutamine, and high perfusate calabove.
cium each increased systolic pressure and forcetime integral in a concentration-dependent manner (Table 1) . Each caused a downward trend in the diastolic pressure. However, despite a 50% increase Data analysis in systolic pressure and a 17% increase in forcetime integral compared to control, ORG 30029 The force-time integral was derived as an estimation of cardiac mechanical work. It was dehad no significant effect on MVO 2 at the lower concentrations. This effect on MVO 2 differed from termined from the pressure tracings above by digitally scanning the cardiac cycle from onset that of dobutamine and high perfusate calcium where a 65% increase in systolic pressure and a of contraction to the next onset of contraction (AdobePhotoshop, Mountain View, CA) and in-17% increase in force-time integral compared to control resulted in a 50% and 41% increase in tegrating the total left ventricular pressure over time. The diastolic portion of the cardiac cycle was MVO 2 , respectively. Developed pressure was effected in a similar manner to force-time integral by the included in the determination of the force-time integral because myocardial energy consumption three agents (Fig. 1) . The different effects on MVO 2 between the agents was less significant at higher has been demonstrated to be determined by ventricular pressures during both systole and diastole concentrations. Coronary flow tended to increase Figure 1 Relationship between changes in developed pressure and myocardial oxygen consumption (top), and force-time integral and myocardial oxygen consumption (bottom) for dobutamine, high perfusate calcium, and ORG 30029 in rat hearts. Dobutamine caused a greater increase in myocardial oxygen consumption for a similar change in force-time integral than did calcium. Both agents caused a greater rise in myocardial oxygen consumption than did ORG 30029.
with 6 m perfusate calcium but not 4 m perof the experiments presented in Table 1 with 31 P NMR. As shown in Table 2 , there were no sigfusate calcium, dobutamine, or ORG 30029.
To elucidate possible mechanisms for the difnificant differences in the phosphate metabolite concentrations; indicating that the production and ferences in contractile economy between the inotropic agents, high energy phosphate concentrautilization of high energy phosphates were in a steady-state. Likewise, lactate production was untions, lactate production, and basal metabolism were determined in hearts perfused at the conaffected by perfusion by each agent. Basal metabolism, as measured in the KCl arrested heart, was centrations that caused the largest differences in contractile economy. High energy phosphate connot significantly altered by each inotropic agent (Table 3) though there was a trend towards an centrations in hearts were determined in a subset Data presented as means ± standard deviation. there were no statistically significant differences between the agents with respect to the parameters measured. DW, dry weight. calcium sensitizing agents and conventional inotropic agents. A study comparing the effects of pimobendan and dobutamine on MVO 2 in dog hearts found no significant difference in the ef-
Discussion
ficiency of contraction between these two agents, though economy increased 14% with pimobendan The present investigation demonstrated significant (Hata et al., 1992) . Another study in dog hearts differences in energetic responses to increased condemonstrated no energetic differences between EMD tractility in perfused rat hearts between the calcium 53998 (another calcium sensitizing agent) and sensitizing agent ORG 30029, the 1 agonist docalcium infusion (de Tombe et al., 1992) . The conbutamine, and high perfusate calcium. These difflicting results between these studies may be due ferences resulted in divergent effects on cardiac to differences in species used, pharmacological acenergetics. The effect of dobutamine and high pertions of the agents, or experimental methods emfusate calcium on cardiac function, metabolism, ployed. The energetics of the isovolumic heart differ and phosphate metabolites by 31 P NMR have been from that of the ejecting heart (Alpert et al., 1992., well described previously (Kingsley-Hickman et al., Suga, 1990) . Thus, it is uncertain whether the 1992). The responses seen in this study are very marked differences in cardiac energetics observed similar to previous reports. To our knowledge, the between agents in this investigation would be found simultaneous effects of ORG 30029 on MVO 2 , phosin the ejecting heart as well. phate metabolites, and function have not been
What are possible mechanisms for the disparate investigated.
responses in MVO 2 between the different inotropic The energetic effects of ORG 30029 seen in the agents employed in the current investigation? current investigation are consistent with those seen Neither lactate production or high energy phosin other trials with other calcium sensitizing agents.
phate concentrations were altered in hearts stimGross et al., demonstrated a similar difference beulated with these agents. Thus, alterations in these tween the calcium sensitizing agent EMD 57033 parameters cannot account for the different effects and dihydroouabain in guinea pig hearts (Gross et on MVO 2 by these inotropic agents. Though basal al., 1993) . This result was consistent with our metabolism tended to increase slightly with comparison of EMD 57033 and dobutamine in rat hearts (Grandis et al., 1995) . However, other studies dobutamine, the 25% increase in MVO 2 with dobutamine in the KCl-arrested heart cannot fully similar increase in force-time integral. These changes occurred without affecting high energy account for the 50% increase in MVO 2 in the beating heart. Furthermore, high perfusate calcium did not phosphate concentrations, lactate production, or basal metabolism. The energetic differences may be affect MVO 2 in the KCl-arrested heart but did increase MVO 2 in the beating heart by 41%. It is accounted for by differences in calcium handling or effects on the myosin-actin interaction. possible that these agents altered the P:O ratio in mitochondria. However, this ratio has been demonstrated to be unaffected in rat hearts stimulated with dobutamine (Kingsley-Hickman et al., 1992) . , 1990, Kawabata and Endoh, 1993 
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